| scholarly article | Q13442814 |
| P50 | author | Meenhard Herlyn | Q16732421 |
| Clemens Krepler | Q61529607 | ||
| P2093 | author name string | Mark Morgan | |
| Eric Brown | |||
| Fiona Simpkins | |||
| Hyoung Kim | |||
| Rugang Zhang | |||
| Erin George | |||
| Ryan Ragland | |||
| Stavros Rafial | |||
| P2860 | cites work | ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 | Q24550952 |
| Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance | Q24672646 | ||
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Caspases: opening the boxes and interpreting the arrows | Q28216089 | ||
| Apoptosis and cancer: mutations within caspase genes | Q28247775 | ||
| Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics | Q28266884 | ||
| PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with | Q90727675 | ||
| ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays | Q28364520 | ||
| ATR disruption leads to chromosomal fragmentation and early embryonic lethality | Q28591433 | ||
| Chk1 and Chk2 kinases in checkpoint control and cancer | Q29617706 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Causes and consequences of replication stress | Q34394094 | ||
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Q34422265 | ||
| Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner | Q34676703 | ||
| ATR prohibits replication catastrophe by preventing global exhaustion of RPA. | Q35051406 | ||
| Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit | Q35131775 | ||
| Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts | Q35448716 | ||
| Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR | Q35640593 | ||
| Chk’ing p53-deficient breast cancers | Q35858171 | ||
| Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells | Q36054977 | ||
| CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiation | Q36280773 | ||
| A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. | Q36908567 | ||
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
| Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines | Q36929175 | ||
| ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. | Q36941455 | ||
| ATR phosphorylates SMARCAL1 to prevent replication fork collapse | Q37064611 | ||
| DNA repair deficiency as a therapeutic target in cancer | Q37110904 | ||
| Death through a tragedy: mitotic catastrophe | Q37135368 | ||
| CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors | Q37168650 | ||
| RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells | Q37271812 | ||
| A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers | Q37558633 | ||
| Tumorgrafts as in vivo surrogates for women with ovarian cancer. | Q37626455 | ||
| Mechanisms of resistance to therapies targeting BRCA-mutant cancers | Q38160737 | ||
| Protein ADP-ribosylation and the cellular response to DNA strand breaks | Q38206322 | ||
| Molecular Pathways: Targeting ATR in Cancer Therapy | Q38585436 | ||
| The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded | Q38787667 | ||
| Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. | Q39559122 | ||
| Characterization of a novel ATR-dependent, Chk1-independent, intra-S-phase checkpoint that suppresses initiation of replication in Xenopus | Q41846285 | ||
| New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair | Q44756445 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| ATR inhibition preferentially targets homologous recombination-deficient tumor cells. | Q54326103 | ||
| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 | ||
| The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin | Q78835035 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 3097-3108 | |
| P577 | publication date | 2016-12-19 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models | |
| P478 | volume | 23 |
| Q92890485 | A decade of clinical development of PARP inhibitors in perspective |
| Q90399238 | ATM-Deficient Cancers Provide New Opportunities for Precision Oncology |
| Q47643551 | ATR Is a Therapeutic Target in Synovial Sarcoma. |
| Q42315217 | ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. |
| Q90239010 | ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells |
| Q55306606 | Advances in therapeutic targeting of the DNA damage response in cancer. |
| Q61136915 | Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance |
| Q92476256 | Applications of patient-derived tumor xenograft models and tumor organoids |
| Q47164964 | BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer |
| Q90562787 | Bayesian inference of hub nodes across multiple networks |
| Q90622524 | Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models |
| Q90827979 | Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations |
| Q57176137 | Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status |
| Q52615755 | Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer |
| Q95660697 | Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells |
| Q98565962 | Combining PARP inhibitors with platinum or ruthenium-based complexes for cancer therapy |
| Q97692537 | Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models |
| Q63446284 | Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference |
| Q96168423 | DNA damage checkpoint kinases in cancer |
| Q96432061 | Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models |
| Q89994199 | Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer |
| Q88875414 | Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma |
| Q90372233 | Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition |
| Q58801181 | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
| Q99548779 | Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach |
| Q64999993 | MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. |
| Q92612315 | Mitotic functions of poly(ADP-ribose) polymerases |
| Q90308673 | Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan |
| Q91564632 | Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma |
| Q89880356 | Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells |
| Q89581160 | PARP and PARG inhibitors in cancer treatment |
| Q64279560 | PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms |
| Q92126687 | Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer |
| Q90142332 | Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells |
| Q92812787 | Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer |
| Q93157621 | Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells |
| Q48534871 | Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer |
| Q97537635 | Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer |
| Q57793601 | State-of-the-art strategies for targeting the DNA damage response in cancer |
| Q89095370 | Targeting ATR in cancer |
| Q90707206 | Targeting DNA repair in cancer: current state and novel approaches |
| Q47111141 | The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells |
| Q95267029 | The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy |
| Q90529610 | The tubal epigenome - An emerging target for ovarian cancer |
| Q89727327 | Therapeutic Application of PARP Inhibitors in Neuro-Oncology |
| Q41552673 | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. |
Search more.